Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01701687
Other study ID # 12050
Secondary ID
Status Completed
Phase N/A
First received October 3, 2012
Last updated July 31, 2015
Start date September 2012
Est. completion date July 2015

Study information

Verified date July 2015
Source University of Nottingham
Contact n/a
Is FDA regulated No
Health authority United Kingdom: Research Ethics Committee
Study type Observational

Clinical Trial Summary

Fibroscan is a non invasive imaging investigation which measures liver stiffness, known to correlate well with liver scarring and cirrhosis on liver biopsy. Indocyanine green is an inert dye which is purely extracted from the blood by liver cells, and is hence an excellent marker of both liver cell function and overall liver blood flow. There is little data for either of these biomarkers regarding outcomes in alcoholic liver disease. We aim to establish the accuracy of these liver biomarkers in predicting important liver related outcomes (death, transplantation and hospital readmission with cirrhosis related consequences) in patients with severe (decompensated) alcoholic liver disease. Moreover, we will assess whether the serial measurement of biomarkers has any impact on alcohol abstinence, motivation or quality of life. Over an 18 month period, 125 consecutive hospital inpatients with decompensated alcoholic liver disease will undergo baseline biomarker measurement, routine blood and urine tests and qualitative questionnaires. These will be measured during their initial hospital admission (0 months) with subsequent repeat measurement during follow up visits at 1, 2, 4 and 6 months. Each study visit time will be in the region of 30-40 minutes to complete these investigations. The end of the study for individual patients will be patient death, liver transplantation or 6 month from study enrolment; whichever occurs first.


Description:

This is a single centre longitudinal cohort feasibility pilot study of patients with decompensated alcoholic liver disease. We aim to recruit 125 consecutive patients with decompensated alcoholic liver disease over an 18 month period. This number is based upon approximately 10 admissions per month to acute liver services with decompensated alcoholic liver disease and includes a presumed 20% dropout rate during follow up, giving a total cohort of 100 patients. Patients will undergo a maximum of 6 months follow up following study recruitment.

The purposes of this study are:

1. To assess the performance of diagnostic liver biomarkers (Indocyanine Green, Fibroscan and blood and urinary biomarkers) in predicting mortality in decompensated alcoholic liver disease.

2. To compare the diagnostic and prognostic end points of these biomarkers with existing cirrhosis prognostic scoring systems (Child Pugh, MELD and UKELD).

3. To assess the performance of diagnostic biomarkers as a therapeutic aid to quality of life and alcohol abstinence.

Potentially eligible patients i.e. adults with decompensated liver disease with alcohol as a major co-factor, and acutely admitted secondary to sequelae of hepatic decompensation, will be approached by an existing member of their clinical care team (The CI & Co-Investigators form part of this team). Any patient who decides to take part in the study will have a baseline inpatient study visit either on their inpatient ward or to the NDDC Biomedical Research Unit (BRU). Subsequent follow up visits will be to the BRU.

Inclusion Criteria:

- Male or female patients 18-75 years of age

- Diagnosis of cirrhosis based upon:

- a) Histological confirmation

- b) Combination of clinical and radiological criteria

- c) Validated non invasive biomarker

- Alcohol as the primary aetiology for liver cirrhosis

- Hospital admission related to decompensated liver disease (e.g. ascites, varices, sepsis, alcoholic hepatitis)

- Active alcohol drinking prior to index hospital admission

Exclusion Criteria:

- Grade 3 or 4 hepatic encephalopathy

- Hepatocellular carcinoma

- Active non hepatic malignancy

- Known complete portal vein thrombosis

- Alcohol abstinence at time of index hospital admission

- Pregnancy

- Active cardiac devices

The research visit will require measurement of ICG clearance, Fibroscan, blood tests, urine tests and questionnaires. They will then be required to attend study visits at 1, 2, 4 and 6 months following the baseline study visit, after which study follow up will cease.

Patients will undergo study visits at the following intervals:

- Baseline visit (study visit 0)

- 1 month (study visit 1)

- 2 months (study visit 2)

- 4 months (study visit 3)

- 6 months (study visit 4)

The following data will be collected for the purposes of this research project at the baseline and subsequent study visits:

- Collection of demography, anthropometry, drug history, smoking, alcohol intake, blood pressure, full blood count, renal function, liver function, coagulation and serum samples

- Brief abdominal examination to detect presence of moderate to severe ascites (for the purposes of Child Pugh score measurement)

- ICG analysis

- Transient elastography (Fibroscan)

- Blood and urinary biomarkers (proteomics and metabonomics)

- Chronic Liver Disease Quality of Life Questionnaire

- Alcohol intake assessments (28 Day AUDIT tool)

- Alcohol STAR tool for qualitative assessment (to assess the influence of Fibroscan/ICG readings on motivation, beliefs and alcohol abstinence)

Demography and history are taken as part of normal clinical care. All patients will be offered standard follow up from both outpatient hepatology clinic and hospital alcohol liaison services throughout the period of study.


Recruitment information / eligibility

Status Completed
Enrollment 36
Est. completion date July 2015
Est. primary completion date July 2015
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

- Male or female patients 18-75 years of age

- Diagnosis of cirrhosis based upon:

- a) Histological confirmation

- b) Combination of clinical and radiological criteria

- c) Validated non invasive biomarker

- Alcohol as the primary aetiology for liver cirrhosis

- Hospital admission related to decompensated liver disease (e.g. ascites, varices, sepsis, alcoholic hepatitis)

- Active alcohol drinking prior to index hospital admission

Exclusion Criteria:

- Grade 3 or 4 hepatic encephalopathy

- Hepatocellular carcinoma

- Active non hepatic malignancy

- Known complete portal vein thrombosis

- Alcohol abstinence at time of index hospital admission

- Pregnancy

- Active cardiac devices (e.g. cardiac pacemaker, implantable cardioverter defibrillator)

Study Design

Observational Model: Cohort, Time Perspective: Prospective


Locations

Country Name City State
United Kingdom Nottingham University Hospitals NHS Trust Nottingham Notts

Sponsors (2)

Lead Sponsor Collaborator
University of Nottingham National Institute for Health Research, United Kingdom

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Liver Related Death The proportion of deaths up to 6 months from the baseline visit directly attributable to consequences of cirrhosis 6 months No
Secondary Non-Liver related death Mortality unrelated to liver disease up to 6 months from baseline study visit 6 months No
Secondary Hospital Readmission Hospital readmission secondary to complications of cirrhosis 6 months No
Secondary Alcohol abstinence Proportion of patients abstinent from alcohol at the 6 month timepoint 6 months No
See also
  Status Clinical Trial Phase
Recruiting NCT05121870 - Treatment With Human Umbilical Cord-derived Mesenchymal Stem Cells for Decompensated Cirrhosis Phase 2
Recruiting NCT05421351 - Immune Profile, Neuronal Dysfunction, Metabolomics and Ammonia in Therapeutic Response of HE in ACLF
Not yet recruiting NCT05086536 - Re-compensation and Its Clinical Characteristics in HBV Decompensated Cirrhosis
Recruiting NCT03820271 - New Prognostic Predictive Models of Mortality of Decompensated Cirrhotic Patients Waiting for Liver Transplantation N/A
Recruiting NCT06134544 - Effect of IMO on Intestinal Microbiota Translocation in Cirrhosis N/A
Recruiting NCT06223893 - CirrhoCare- Using Smart-phone Technology to Enhance Care and Access to Treatment for Cirrhosis N/A
Completed NCT02219477 - A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Ribavirin in Adults With Genotype 1 and Ombitasvir/Paritaprevir/Ritonavir With Ribavirin in Adults With Genotype 4 Chronic Hepatitis C Virus Infection and Decompensated Cirrhosis Phase 3
Recruiting NCT05734001 - Rotational Thromboelastometry Versus Conventional Haemostatic Tests in Children With Decompensated Cirrhosis Undergoing Invasive Procedures. N/A
Terminated NCT04775329 - Primary Prophylaxis for Spontaneous Bacterial Peritonitis Phase 2/Phase 3
Recruiting NCT04422223 - Prospective Cohort Study of Disease and Outcomes in Cirrhosis
Recruiting NCT02786017 - Injectable Collagen Scaffold™ Combined With HUC-MSCs Transplantation for Patients With Decompensated Cirrhosis Phase 1/Phase 2
Completed NCT01326949 - Transjugular Intrahepatic Portosystemic Shunt (TIPS) for Prevention of Variceal Rebleeding in Cirrhotic Patients With Portal Vein Thrombosis N/A
Recruiting NCT06396897 - Hospital @ Home Model of Care for Cirrhosis
Not yet recruiting NCT06306781 - A Clinical Trial Evaluating the Safety, Tolerability, and Preliminary Efficacy of HCL001 Cell Injection (Homologous Allogeneic Hepatocytes) in Patients With Decompensated Cirrhosis N/A
Recruiting NCT05227846 - Human Umbilical Cord-derived Mesenchymal Stem Cells for Decompensated Cirrhosis (MSC-DLC-1) Phase 1
Not yet recruiting NCT05937048 - Coagulation Parameters With Albumin in Decompensated Cirrhosis (CoPA-D). N/A
Active, not recruiting NCT03205345 - Emricasan, a Caspase Inhibitor, for Treatment of Subjects With Decompensated NASH Cirrhosis Phase 2
Terminated NCT03462576 - Companion Protocol for Methacetin Breath Test (MBT) in Conatus Protocol IDN-6556-17
Not yet recruiting NCT05224960 - Human Umbilical Cord-derived Mesenchymal Stem Cells for Decompensated Cirrhosis (MSC-DLC-2) Phase 2
Terminated NCT04112199 - A Study for Evaluation of BIV201 to Reduce Ascites and Complications in Patients With Cirrhosis and Refractory Ascites Phase 2